MedTrace Logo

Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe Drugs

NCT00920088 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2010-11-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of GSK2448761 on CYP450 metabolic probes and to evaluate the 2-way interaction between GSK2448761 and two ritonavir-boosted protease inhibitors that are commonly used in HIV-infected subjects.

Conditions

  • Healthy Subjects
  • Infection, Human Immunodeficiency Virus

Interventions

DRUG

darunavir/ritonavir

DRV/RTV 600/100mg

DRUG

lopinavir/ritonavir

LPV/RTV 400/100mg

DRUG

Midazolam

Midazolam 3mg

DRUG

Dextromethorphan

Dextromethorphan 30mg

DRUG

Flurbiprofen

Flurbiprofen 50mg

DRUG

GSK2248761

NNRTI under investigation

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2009-11-30
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00920088 on ClinicalTrials.gov